CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

First patient receives BHB810 in BigHat Biosciences’ Phase I study

Phase 1BHB810Positive
AI Analysis

Summary

BigHat Biosciences has dosed the first patient in a Phase I clinical trial of BHB810 for treating gastric cancer and advanced gastrointestinal malignancies.

Clinical Trial Data

Phase

Phase I

Patients

1

Importance:5/10
Sentiment:
0.30
Phase 1 initiationgastric cancerGI malignanciesclinical trial
Related Companies

Read the original article

Published by Clinical Trials Arena on September 2, 2026 8:53 AM

Read Original